Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley Campbell sold 75,000 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $14.31, for a total value of $1,073,250.00. Following the sale, the chief executive officer directly owned 1,021,180 shares in the company, valued at approximately $14,613,085.80. The trade was a 6.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Amicus Therapeutics Stock Down 0.6%

FOLD traded down $0.08 during trading on Thursday, hitting $14.27. The company had a trading volume of 10,838,894 shares, compared to its average volume of 11,160,116. Amicus Therapeutics, Inc. has a 1-year low of $5.51 and a 1-year high of $14.38. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09. The company has a market cap of $4.40 billion, a PE ratio of -356.66 and a beta of 0.42. The business has a 50-day moving average of $12.03 and a 200-day moving average of $9.18.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The business had revenue of $169.06 million for the quarter, compared to analyst estimates of $165.24 million. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The company’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.10 EPS. As a group, analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Analyst Ratings Changes

FOLD has been the subject of several recent research reports. Leerink Partners lowered Amicus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $17.00 to $14.50 in a report on Monday, December 29th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $14.50 price objective (down previously from $16.00) on shares of Amicus Therapeutics in a report on Thursday. TD Cowen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 target price for the company. in a research note on Monday, December 22nd. Cantor Fitzgerald lowered shares of Amicus Therapeutics from an “overweight” rating to a “hold” rating and dropped their price target for the company from $21.00 to $14.50 in a research note on Friday, December 19th. Finally, Guggenheim downgraded Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amicus Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $15.55.

Institutional Trading of Amicus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in FOLD. Goldman Sachs Group Inc. boosted its holdings in shares of Amicus Therapeutics by 7.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,703,577 shares of the biopharmaceutical company’s stock worth $22,061,000 after buying an additional 194,213 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Amicus Therapeutics by 11.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,072,474 shares of the biopharmaceutical company’s stock valued at $8,751,000 after purchasing an additional 113,803 shares during the last quarter. Intech Investment Management LLC increased its stake in shares of Amicus Therapeutics by 37.1% in the first quarter. Intech Investment Management LLC now owns 170,922 shares of the biopharmaceutical company’s stock worth $1,395,000 after purchasing an additional 46,218 shares during the period. Strs Ohio acquired a new position in shares of Amicus Therapeutics during the 1st quarter worth about $30,000. Finally, Tempus Wealth Planning LLC boosted its stake in Amicus Therapeutics by 80.0% during the 2nd quarter. Tempus Wealth Planning LLC now owns 53,132 shares of the biopharmaceutical company’s stock valued at $304,000 after purchasing an additional 23,619 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure?based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.